Explore WARF Inventions and Patents
WARF’s portfolio of more than 1,600 patented technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.
Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.
Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.
Metformin is attractive because its safety has been established over decades in diabetic patients worldwide. As such, there seem to be few barriers to its clinical implementation as a cancer therapeutic in combination with TRAIL receptor agonists. Metformin is commercially available as Glucophage® or in generic form.
The α/β-peptide mimics (or foldamers) can be tailored to target a variety of different proteins and protein-protein interactions. Given their small size (39 amino acids) relative to full-length Z-domains (59 amino acids), the new peptide mimics are easier to synthesize and modify.
The reaction takes place at ambient temperature and pressure using a TEMPO mediator. Unlike previous methods, the process does not require a precious metal catalyst.
In the process, lignocellulosic material is reacted with water and gamma-valerolactone (GVL) – an organic solvent derived from biomass. This occurs in the presence of an acid catalyst under moderate temperatures, and results in the conversion of water-insoluble to water-soluble carbohydrates. These desired products are partitioned into an aqueous layer, where they can be recovered, concentrated and purified. The GVL separates into another layer to be recycled.
To obstruct this process, the researcher has created a recombinant peptide that competes with Sdc1 for binding partners. The new peptide mimics Sdc1 but is harmless. It is called SSTNHER2. It can be administered as a drug and combined with cancer patients’ other therapies.